Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1967 1
1971 1
1973 1
1974 1
1975 1
1976 3
1978 3
1979 2
1980 1
1981 3
1982 4
1984 3
1985 4
1986 4
1987 8
1988 5
1989 7
1990 7
1991 10
1992 12
1993 11
1994 13
1995 22
1996 16
1997 17
1998 24
1999 30
2000 28
2001 20
2002 19
2003 13
2004 24
2005 27
2006 18
2007 22
2008 37
2009 24
2010 35
2011 48
2012 54
2013 45
2014 49
2015 49
2016 55
2017 71
2018 60
2019 74
2020 64
2021 34
2022 10
2023 11
2024 85
2025 79
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

80 results

Results by year

Filters applied: Meta-Analysis, Randomized Controlled Trial, Systematic Review, in the last 1 year, Child: birth-18 years, Infant: birth-23 months, Newborn: birth-1 month, Infant: 1-23 months, Preschool Child: 2-5 years, Child: 6-12 years, Adolescent: 13-18 years. Clear all
Page 1
Clinical evaluation of MyoCare in Europe (CEME) for myopia management: One-year results.
Alvarez-Peregrina C, Sanchez-Tena MA, Villa-Collar C, Martinez-Perez C, de Corcuera-Terrero B, Liu N, Li W, Sankaridurg P, Ohlendorf A; Clinical Evaluation of MyoCare in Europe – the CEME Study Group. Alvarez-Peregrina C, et al. Ophthalmic Physiol Opt. 2025 Jun;45(4):1025-1035. doi: 10.1111/opo.13517. Epub 2025 Apr 29. Ophthalmic Physiol Opt. 2025. PMID: 40296784 Free PMC article. Clinical Trial.
Radiographic and visual response to the type II RAF inhibitor tovorafenib in children with relapsed/refractory optic pathway glioma in the FIREFLY-1 trial.
Nysom K, Kilburn LB, Leary SES, Landi DB, de Vos-Kerkhof E, Perreault S, Witt O, Ziegler DS, Hernáiz Driever P, Franson AT, Baxter PA, Whipple NS, Kline C, Segal D, Jabado N, Bailey S, McCowage G, Hansford JR, Khuong-Quang DA, Gottardo NG, Hassall T, Han JW, Yalon Oren M, Chi SN, Qiu J, Da Costa D, Govinda Raju S, Manley P, Hargrave D. Nysom K, et al. Neuro Oncol. 2025 Jun 21;27(5):1341-1355. doi: 10.1093/neuonc/noae274. Neuro Oncol. 2025. PMID: 39700439 Free PMC article. Clinical Trial.
Baseline characteristics of children in the Early Glasses Study.
Steltman JS, Nordmann M, Sanders D, Asjes-Tydeman WL, Dehpoor T, Tissen I, van Ommen R, Wiersma-Hartman C, van Keulen MM, Bakker D, Loudon SE, Simonsz HJ. Steltman JS, et al. Graefes Arch Clin Exp Ophthalmol. 2025 Feb;263(2):555-563. doi: 10.1007/s00417-024-06621-8. Epub 2024 Sep 5. Graefes Arch Clin Exp Ophthalmol. 2025. PMID: 39235501 Free PMC article. Clinical Trial.